INmune Bio announces analyses from Phase 2 MINDFuL trial, endpoint not met

INmune Bio (INMB) announced that additional analyses from its Phase 2 MINDFuL trial evaluating XPro, a novel selective soluble TNF inhibitor, will be released in an oral presentation at the Alzheimer’s Association International Conference, AAIC, in Toronto, Canada. The MINDFuL trial is a double-blind, Phase 2 proof-of-concept study examining the potential of XPro to slow cognitive decline in early-stage Alzheimer’s disease by targeting neuroinflammation. While the primary endpoint was not met in the overall modified-intent-to-treat mITT group, key changes in clinical measures of cognition, behavior, and AD-related biomarkers demonstrated a consistent benefit of treatment with XProTM after 6 months in a subpopulation of patients with biomarker confirmed amyloid-beta pathology and greater than or equal to2 of the blood biomarkers of systemic inflammation.